Brazilian National Health Surveillance Agency, ANVISA, has granted approval for the expansion of PTC Therapeutics’ Translarna (ataluren) indication to include ambulatory children in the country aged two to five years.

The approval allows Translarna to include ambulatory children with nonsense mutation Duchenne muscular dystrophy (Duchenne).

Discovered and developed by PTC Therapeutics, Translarna is a protein restoration treatment that will enable the functioning of protein formation in patients suffering from genetic disorders that are caused by a nonsense mutation.

The treatment was formerly approved for use by patients aged five years and above.

Duchenne is a genetic disorder that leads to muscle function that will rapidly worsen with children often becoming dependents on wheelchairs in their early adolescence and eventually needing an artificial ventilator for breathing.

Translarna is the tradename of ataluren and has shown potentially slow disease progression and improvement in patient outcomes during clinical trials and in real-time use.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Additionally, it is claimed to be the only treatment for Duchenne.

PTC Therapeutics CEO Stuart Peltz said: “Expanding access to Translarna to children with nonsense mutation Duchenne in Brazil is important to us.

“We know that with Duchenne, early diagnosis and treatment gives children the best chance of preserving muscle function and delaying the progression of the disease.”

Translarna is licensed for use in the European Economic Area to treat nonsense mutation Duchenne in two years and above aged ambulatory patients.

In the US, Translarna is an investigational new drug.

Last month, the company reported real-world data from the STRIDE patient registry which showed that Translarna treatment in boys with nonsense mutation Duchenne delayed loss of ambulation by over five years.

This was in comparison to the standard of care alone.